CoChat

Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function

Open access
Gruber, Staci A., Sagar, Kelly A., Dahlgren, Mary K., Racine, Megan T., Smith, Rosemary T., Lukas, Scott E. · 2016 · Frontiers in Pharmacology
Cited by 79

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Currently, 25 states and Washington DC have enacted full medical marijuana (MMJ) programs while 18 states allow limited access to MMJ products. Limited access states permit low (or zero) tetrahydrocannabinol (THC) and high cannabidiol (CBD) products to treat specified conditions such as uncontrolled epilepsy. Although MMJ products are derived from the same plant species as recreational MJ, they are often selected for their unique cannabinoid constituents and ratios, not typically sought by recreational users, which may impact neurocognitive outcomes. To date, few studies have investigated the potential impact of MMJ use on cognitive performance, despite a well-documented association between recreational marijuana (MJ) use and executive dysfunction. The current study assessed the impact of 3 months of MMJ treatment on executive function, exploring whether MMJ patients would experience improvement in cognitive functioning, perhaps related to primary symptom alleviation. As part of a larger longitudinal study, 24 patients certified for MMJ use completed baseline executive function assessments and 11 of these so far have returned for their first follow-up visit 3 months after initiating treatment. Results suggest that in general, MMJ patients experienced some improvement on measures of executive functioning, including the Stroop Color Word Test and Trail Making Test, mostly reflected as increased speed in completing tasks without a loss of accuracy. On self-report questionnaires, patients also indicated moderate improvements in clinical state, including reduced sleep disturbance, decreased symptoms of depression, attenuated impulsivity, and positive changes in some aspects of quality of life. Additionally, patients reported a notable decrease in their use of conventional pharmaceutical agents from baseline, with opiate use declining more than 42%. While intriguing, these findings are preliminary and warrant further investigation at additional time points and in larger sample sizes. Given the likelihood of increased MMJ use across the country, it is imperative to determine the potential impact of short- and long-term treatment on cognitive performance as well as the efficacy of MMJ treatment itself.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2016.00355

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 80

  1. ArcView Market Research, 2016, The State of Legal Marijuana Markets, 2nd Edn.
  2. Auer, 2016, Association between lifetime marijuana use and cognitive function in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) Study, JAMA Intern. Med., 176, 352, 10.1001/jamainternmed.2015.7841 · DOI · Paper page
  3. Ballantyne, 2008, Efficacy of opioids for chronic pain: a review of the evidence, Clin. J. Pain, 24, 469, 10.1097/AJP.0b013e31816b2f26 · DOI · Paper page
  4. Baron, 2015, Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been .…, Headache, 55, 885, 10.1111/head.12570 · DOI · Paper page
  5. Beck, 1990, Manual for the Beck Anxiety Inventory
  6. Beck, 1961, An inventory for measuring depression, Arch. Gen. Psychiatry, 4, 561, 10.1001/archpsyc.1961.01710120031004 · DOI · Paper page
  7. Becker, 2014, Neurocognition in college-aged daily marijuana users, J. Clin. Exp. Neuropsychol., 36, 379, 10.1080/13803395.2014.893996 · DOI · Paper page
  8. Berg, 1948, A simple objective technique for measuring flexibility in thinking, J. Gen. Psychol., 39, 15, 10.1080/00221309.1948.9918159 · DOI · Paper page
  9. Birch, 1889, The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning, Lancet, 133, 625, 10.1016/S0140-6736(00)30567-0 · DOI
  10. Blessing, 2015, Cannabidiol as a potential treatment for anxiety disorders, Neurotherapeutics, 12, 825, 10.1007/s13311-015-0387-1 · DOI · Paper page
  11. Booth, 2003, Cannabis: A History
  12. Borelli, 2013, Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease, Biochem. Pharmacol., 85, 1306, 10.1016/j.bcp.2013.01.017 · DOI · Paper page
  13. Borgwardt, 2008, Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition, Biol. Psychiatry, 64, 966, 10.1016/j.biopsych.2008.05.011 · DOI · Paper page
  14. Boychuk, 2015, The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review, J. Oral Facial Pain Headache, 29, 7, 10.11607/ofph.1274 · DOI · Paper page
  15. Braga, 2012, Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder, Psychiatry Res., 200, 242, 10.1016/j.psychres.2012.05.025 · DOI
  16. Buysse, 1989, The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research, Psychiatry Res., 28, 193, 10.1016/0165-1781(89)90047-4 · DOI · Paper page
  17. Center for Behavioral Health Statistics Quality, 2015, Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50)
  18. Centers for Disease Control Prevention, 2015, Number and Age-Adjusted Rates of Drug-poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 2000–2014
  19. Consroe, 1991, Controlled clinical trial of cannabidiol in Huntington's disease, Pharmacol. Biochem. Behav., 40, 701, 10.1016/0091-3057(91)90386-G · DOI · Paper page
  20. Cousijn, 2013, Cannabis dependence, cognitive control and attentional bias for cannabis words, Addict. Behav., 38, 2825, 10.1016/j.addbeh.2013.08.011 · DOI
  21. Crane, 2013, Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users, J. Int. Neuropsychol. Soc., 19, 1009, 10.1017/S135561771300088X · DOI · Paper page
  22. Crane, 2015, Neuropsychological sex differences associated with age of initiated use among young adult cannabis users, J. Clin. Exp. Neuropsychol., 37, 389, 10.1080/13803395.2015.1020770 · DOI · Paper page
  23. Dahlgren, 2016, Marijuana use predicts cognitive performance on tasks of executive function, J. Stud. Alcohol Drugs, 77, 298, 10.15288/jsad.2016.77.298 · DOI
  24. Degenhardt, 2015, Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study, Drug Alcohol Depend., 147, 144, 10.1016/j.drugalcdep.2014.11.031 · DOI · Paper page
  25. Department of Justice, 2016a, Denial of Petition to Initiate Proceedings to Reschedule Marijuana
  26. Department of Justice, 2016b, Applications to Become Registered Under the Controlled Substances Act to Manufacture Marijuana to Supply Researchers in the United States (21 CFR Part 1301, Docket No. DEA-447)
  27. Deshpande, 2015, Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials, Can. Fam. Physician, 61, E372
  28. Dougherty, 2013, Impulsivity, attention, memory, and decision-making among adolescent marijuana users, Psychopharmacology (Berl)., 226, 307, 10.1007/s00213-012-2908-5 · DOI · Paper page
  29. Ehrenreich, 1999, Specific attentional dysfunction in adults following early start of cannabis use, Psychopharmacology (Berl)., 142, 295, 10.1007/s002130050892 · DOI · Paper page
  30. Eisenberg, 2014, The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study, J. Pain Palliat. Care Pharmacother., 28, 216, 10.3109/15360288.2014.941130 · DOI
  31. ElSohly, 2016, Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States, Biol. Psychiatry, 79, 613, 10.1016/j.biopsych.2016.01.004 · DOI · Paper page
  32. Englund, 2013, Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment, J. Psychopharmacol., 27, 19, 10.1177/0269881112460109 · DOI · Paper page
  33. Englund, 2016, The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial, J. Psychopharmacol. (Oxford)., 30, 140, 10.1177/0269881115615104 · DOI · Paper page
  34. Flachenecker, 2014, Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice–results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity, Eur. Neurol., 71, 271, 10.1159/000357427 · DOI · Paper page
  35. Fontes, 2011, Cannabis use before age 15 and subsequent executive functioning, Br. J. Psychiatry, 198, 442, 10.1192/bjp.bp.110.077479 · DOI · Paper page
  36. Fried, 2005, Neurocognitive consequences of marihuana–a comparison with pre-drug performance, Neurotoxicol. Teratol., 27, 231, 10.1016/j.ntt.2004.11.003 · DOI · Paper page
  37. Giacoppo, 2015, Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis, Eur. Rev. Med. Pharmacol. Sci., 19, 4906
  38. Giedd, 1999, Brain development during childhood and adolescence: a longitudinal MRI study, Nat. Neurosci., 2, 861, 10.1038/13158 · DOI · Paper page
  39. Grinspoon, 1997, Marihuana: The Forbidden Medicine
  40. Gruber, 2012b, Age of onset of marijuana use impacts inhibitory processing, Neurosci. Lett., 511, 89, 10.1016/j.neulet.2012.01.039 · DOI · Paper page
  41. Gruber, 2012a, Age of onset of marijuana use and executive function, Psychol. Addict. Behav., 26, 496, 10.1037/a0026269 · DOI · Paper page
  42. Gul, 2015, Practice and colour-word integration in Stroop interference, Psicológica, 36, 37
  43. Hanson, 2014, Adolescent marijuana users have elevated risk-taking on the balloon analog risk task, J. Psychopharmacol. (Oxford)., 28, 1080, 10.1177/0269881114550352 · DOI
  44. Izzo, 2012, Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice, Br. J. Pharmacol., 166, 1444, 10.1111/j.1476-5381.2012.01879.x · DOI · Paper page
  45. Jackson, 2016, Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies, Proc. Natl. Acad. Sci. U.S.A., 113, E500, 10.1073/pnas.1516648113 · DOI · Paper page
  46. Jacobus, 2015, Neuropsychological performance in adolescent marijuana users with co-occurring alcohol use: a three-year longitudinal study, Neuropsychology, 29, 829, 10.1037/neu0000203 · DOI · Paper page
  47. Jacobus, 2014, Effects of cannabis on the adolescent brain, Curr. Pham. Des., 20, 2186, 10.2174/13816128113199990426 · DOI · Paper page
  48. Johnston, 2015, Monitoring the Future National Survey Results on Drug Use: 1975-2015: Overview: Key Findings on Adolescent Drug Use.
  49. Joy, 1999, Marijuana and Medicine: Assessing the Science Base
  50. Lezak, 2004, Neuropsychological Assessment, 4th Edn
  51. Lisdahl, 2012, Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults, J. Int. Neuropsychol. Soc., 18, 678, 10.1017/S1355617712000276 · DOI · Paper page
  52. MacLeod, 1991, Half a century of research on the stroop effect: an integrative review, Psychol. Bull., 109, 163, 10.1037/0033-2909.109.2.163 · DOI · Paper page
  53. Medina, 2007, Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence, J. Int. Neuropsychol. Soc., 13, 807, 10.1017/S1355617707071032 · DOI · Paper page
  54. Mokrysz, 2016, Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study, J. Psychopharm., 30, 159, 10.1177/0269881115622241 · DOI · Paper page
  55. Patti, 2016, Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity, J. Neurol Neurosurg. Psychiatry., 87, 944, 10.1136/jnnp-2015-312591 · DOI · Paper page
  56. Patton, 1995, Factor structure of the Barratt impulsiveness scale, J. Clin. Psychol., 51, 768, 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1 · DOI · Paper page
  57. Pope, 2003, Early-onset cannabis use and cognitive deficits: what is the nature of the association?, Drug Alcohol Depend., 69, 303, 10.1016/S0376-8716(02)00334-4 · DOI · Paper page
  58. Potter, 1917, Cannabis, 195
  59. Press, 2015, Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy, Epilepsy Behav., 45, 49, 10.1016/j.yebeh.2015.02.043 · DOI · Paper page
  60. Ringen, 2010, Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia, Psychol. Med., 40, 1337, 10.1017/S0033291709991620 · DOI · Paper page
  61. Rosenblum, 2008, Opioids and the treatment of chronic pain: controversies, current status, and future directions, Exp. Clin. Psychopharmacol., 16, 405, 10.1037/a0013628 · DOI · Paper page
  62. Ryan-Ibarra, 2015, Prevalence of medical marijuana use in California, 2012, Drug Alcohol Rev., 34, 141, 10.1111/dar.12207 · DOI
  63. Sagar, 2015, The impact of initiation: early onset marijuana smokers demonstrate altered Stroop performance and brain activation, Dev. Cogn. Neurosci., 16, 84, 10.1016/j.dcn.2015.03.003 · DOI · Paper page
  64. Sagar, 2016, Joint effects: a pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood, PLoS ONE, 11, e0157060, 10.1371/journal.pone.0157060 · DOI
  65. Shinjyo, 2013, The effect of cannabichromene on adult neural stem/progenitor cells, Neurochem. Int., 63, 432, 10.1016/j.neuint.2013.08.002 · DOI
  66. Shuster, 2016, Early onset marijuana use is associated with learning inefficiencies, Neuropsychology, 30, 405, 10.1037/neu0000281 · DOI
  67. Silver, 2016, Marijuana's $40 Billion Dollar Green Rush, Forbes
  68. Sobell, 1998, Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations, Br. J. Addict., 83, 393, 10.1111/j.1360-0443.1988.tb00485.x · DOI · Paper page
  69. Solowij, 2012, Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents, Psychopharmacology (Berl)., 219, 575, 10.1007/s00213-011-2486-y · DOI
  70. Tait, 2011, Cannabis use and cognitive function: 8-year trajectory in a young adult cohort, Addiction, 106, 2195, 10.1111/j.1360-0443.2011.03574.x · DOI · Paper page
  71. Tamm, 2013, Impact of ADHD and cannabis use on executive functioning in young adults, Drug Alcohol Depend., 133, 607, 10.1016/j.drugalcdep.2013.08.001 · DOI · Paper page
  72. Therapeutic Hemp Medical Access Act, 2015, Therapeutic Hemp Medical Access Act of
  73. Vytal, 2013, The complex interaction between anxiety and cognition: insight from spatial and verbal working memory, Front. Hum. Neurosci., 7, 10.3389/fnhum.2013.00093 · DOI · Paper page
  74. Wachtel, 2002, Comparison of the subjective effects of Δ9-tetrahydrocannabinol and marijuana in humans, Psychopharmacology (Berl)., 161, 331, 10.1007/s00213-002-1033-2 · DOI · Paper page
  75. Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med. Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
  76. Wechsler, 1997, Wechsler Adult Intelligence Scale, 3rd Edn. (WAIS-III)
  77. Wechsler, 1999, Wechsler Abbreviated Scale of Intelligence
  78. Wilkie, 2016, Medical marijuana use in oncology: a review, JAMA Oncol., 10.1001/jamaoncol.2016.0155 · DOI · Paper page
  79. Winward, 2014, Heavy alcohol use, marijuana use, and concomitant use by adolescents are associated with unique and shared cognitive decrements, J. Int. Neuropsychol. Soc., 20, 784, 10.1017/S1355617714000666 · DOI · Paper page
  80. Zeiger, 2010, Subjective effects to marijuana associated with marijuana use in community and clinical subjects, Drug Alcohol Depend., 109, 161, 10.1016/j.drugalcdep.2009.12.026 · DOI

Cited by

Metadata

Authors
Gruber, S. A., Sagar, K. A., Dahlgren, M. K., Racine, M. T., Smith, R. T., & Lukas, S. E.
Venue
Frontiers in Pharmacology
Published
2016-10-13
Volume
7
Pages
355-355
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2531714917
Cited by
79
References
19
FWCI
7.26
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.